3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
4
Sarcoma
1
Gynecologic
1
CNS
1
Conditions
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
Temozolomide
79
Magnetic Resonance Spectroscopy
69
Specimen Handling
45
Radiotherapy
42
Bevacizumab
29
Radiosurgery
27
Cyclophosphamide
27
Radiation
20
pembrolizumab
19
Blood Specimen Collection
19
fludarabine
16
Nivolumab
16
Irinotecan
15
Carboplatin
13
Biopsy
13
Etoposide
12
Vincristine
11
Pemetrexed
11
Lomustine
11
dinutuximab
9
Surgical Procedures, Operative
9
trametinib
8
abemaciclib
8
Ipilimumab
8
Fluorodeoxyglucose F18
8
naxitamab
7
fluciclovine F-18
7
Watchful Waiting
7
Topotecan
7
Proton Therapy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
RAD1901
×
CNS
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled